Beijing Minhai Biotechnology Co.,Ltd
Beijing Minhai Biotechnology Co.,Ltd.(referred to as "Company") is a modern biotechnology enterprise specialized in R&D, production and distribution of vaccines. Its mission is to prevent infectious diseases and to treat people through research, development, production and delivery of vaccines, and to improve human health. Company was founded in June 2004, with a registered capital of 200 million RMB and a total asset of 900 million RMB. Minhai has undertaken projects of National"863" program and Grand Science and Technology Special Project from Beijing also, company has established well technical connection with WHO and other international organizations.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
[Specification] 0.5 ml per bottle after reconstitution. Each dose for human use is 0.5 ml, containing measles and rubella live virus not less than 3.0 lgCCID50.
[Vaccination subjects]For people older than 8 months susceptible to measles and rubella virus.
[Function and use]The vaccination can stimulate the body to produce immunity against measles and rubella virus. This product is used for the prevention of measles and rubella.
[Shelf life] 18 months
[Highlights]
•This product is the first one in China which got throμgh the national GMP inspction base on new version.
•High-efficiency、safety、stability •There are only two manufacturers whom produce MR vaccine in China, our company was included,and the MR vaccine is under EPI program, purchased by goverment.
•30% market share in China
•Marketed in Incepta
•Being registered in Thailand, Philippines and Pakistan
